Categories
Entertainment

James Fortune sues Turkey Leg cabin proprietor over unpaid load

Turkey leg hut is involved in another legal dispute. This time a gospel singer James Fortune and his wife Rhaquele have filed a lawsuit against the popular restaurant.

TSR previously reported that Turkey Leg Hut was forced to close due to “35 serious health code violations.” However, the restaurant claimed on social media that it was closed for renovations.

RELATED: Houston Health Department closes Turkey Leg Hut for 35 health code violations

Details of Gospel Singer's Lawsuit Against Turkey Leg Hut

KHOU11 reports that James Fortune and his wife Nakia Price, owner of Turkey Leg Hut, are suing after investing $300,00 in the restaurant. James and Rhaquele met Turkey Leg Hut owner Nakia Price and her husband Lyndell at the venue in 2018. In December, during the Prices' divorce proceedings, the Fortunes loaned Nakia $100,000.

Months later, Nakia frantically called Rhaquele to tell her that creditors were seizing her business assets and she needed more financial support. In response, the Fortunes loaned her another $100,000.

“She was hysterical because the inspectors were physically there seizing assets and so she needed immediate financial support,” Rhaquele said.

Soon after, the Fortunes invested $180,000 to acquire 15% of Turkey Leg Hut. The following month, Nakia told them she couldn't pay the bills, so Rhaquele had to use her personal card for food, supplies and staff wages.

“By then we’re at, you know, $300,000. A month after we gave the money, they filed for bankruptcy. We realize they are now millions in debt,” James added.

The Fortunes also covered employees' wages when the restaurant failed, hoping to keep the business afloat. This week, the Fortunes filed a lawsuit against Nakia Price to get their money back. The lawsuit alleges she defrauded them about Turkey Leg Hut's financial condition and falsely represented that the restaurant was “unencumbered and free of any liabilities” when she sold them partial ownership.

Social media reactions

The housemates were quick to respond to the news about Fortunes and the Prices in the comments section of The Shade Room.

Instagram user @icecube_shah wrote: “They literally had a million-dollar business and screwed it up by being shy people.”

Instagram user @_suckafreesi wrote: What went wrong after they loaned her the first 50,000?”

While Instagram users @nolasaintsgirl504 wrote: My dad always said, 'If you're going to lend someone money, make sure you can afford it. You'll probably never get it back.'

Then Instagram user @whitneyyy_nicole wrote: Wow!!! This is proof that people on social media are living a wrong lifestyle.”

Another Instagram user @twiylla wrote: It’s ironic that they’re called Fortune and Price.”

Instagram user @hec_wooder_ice wrote: If they had let people come to dinner in their pajamas, all of this could have been avoided.”

Finally, Instagram user @bkbabyy06 wrote: Lawyers have a damn hard time in 2024. Litigation is flying left and right.”

More details on Turkey Leg Hut closure

The Shade Room previously reported that inspectors discovered 35 violations at the Turkey Leg Hut on Almeda Road in Houston, citing conditions that endanger public health.

According to Fox26Houston, the restaurant violated health codes related to improper containers, pest control, flooring, ventilation and other issues. Turkey Leg Hut announced on Instagram that it will remain closed until Sunday, September 22nd for renovations to ensure a better dining experience for customers. Despite these promises, the health department has not set a reopening date. KHOU11 reports that health officials are requiring the restaurant to remain closed until the issues are resolved and a subsequent health inspection is passed.

What do you think, roommates?

Categories
Technology

Spain's tech sector affords perception into Draghi's 'innovation hole disaster'

This month the European Commission published Mario Draghi's long-awaited EU Competitiveness Report. His most important insight? The EU must bridge the innovation gap to avoid an economic downturn. According to the report, only four of the world's top 50 technology companies are based in Europe.

In his address to the European Parliament, the former Italian Prime Minister said:

“The core problem in Europe is that no new companies with new technologies are emerging in our economy. In fact, there is no company in the EU with a market capitalization above 100 billion euros that was founded from scratch in the last fifty years. All six US companies valued at over €1 trillion were founded during this period.”

Therefore, many European entrepreneurs prefer to get funding from US venture capitalists and expand in the US market, Draghi added. “Between 2008 and 2021, almost 30% of ‘unicorns’ founded in Europe – startups valued at over $1 billion – moved their headquarters abroad.”

The

The latest rumors from the EU tech scene, a story from our wise founder Boris and questionable AI art. It's free in your inbox every week. Register now!

How can Europe prevent these future major technological potentials from migrating to greener areas?

Perhaps the experience of the young Spanish technology center Valencia can provide insight into the background of this “soonicorn brain drain”.

Valencia's fast-growing startup ecosystem

Valencia, Spain's third largest city, has worked hard in recent years to transform itself into a technology and innovation hub.

Although the city has an average of 300 days of sunshine a year, it has long been overshadowed by its big brothers Madrid and Barcelona when it comes to technology – until now.

According to the Startup Observatory, the number of startups in Valencia increased by 16% during 2023. Meanwhile, startup ranking platform Seedtable shows that 139 of the city's startups have secured a total of $824 million in funding so far this year.

“This growth is due to a combination of a solid support environment, access to financing, qualified talent and favorable public policies, as well as Valencia’s ability to attract international talent and adapt to new technological trends,” says Nacho Mas, CEO of Startup Valencia.

In 2017, Startup Valencia was founded as a non-profit organization with the aim of making the city an internationally recognized technology center by supporting the growth of entrepreneurship, leveraging the scientific and technical talent of its universities and finding ways to scale digital projects.

Alongside these initiatives, it organizes an annual technology event, VDS, to bring together international VCs, speakers and entrepreneurs with the minds behind Valencia's fast-growing ecosystem.

VDS2024, now in its seventh year and taking place from October 23rd to 24th, will welcome more than 12,000 participants, more than 2,500 start-ups and more than 700 investors with assets of more than 200 billion euros in the futuristic City of Arts and sciences under the motto “Embracing Evolution”: Invest in the leaders of tomorrow.

But despite the great strides the city's tech leaders have made to create growth in a short period of time, Mas believes more changes need to be made at the policy level to support tech hub initiatives like hers.

In an interview with Business Insider in June, Mas argued that “there is a lack of a culture of innovation support in Spain,” citing several shortcomings he found in the country's recent startup law, including benefits and support for startups in later phases.

Spain's startup law

The Spanish startup law, which came into force on January 1, 2023, had been in the works since 2018. Some of the key elements of the final law are aimed at improving tax incentives and subsidies and making it easier to attract top talent. This includes:

  • A reduced corporate tax rate of 15% (previously 25%) for the first four years, starting with the first profitable year and a deferral of tax payments for up to 12 months without interest, promoting liquidity in the initial phase.
  • The tax exemption for stock options (used as employee compensation) will be increased from €12,000 to €50,000 per year, making it more attractive for startups to reward employees with equity.
  • Easier access to public funding and innovation grants, particularly for research and development (R&D) projects, as well as improved tax deductions for R&D activities.
  • New programs and tax incentives for foreign talent, including the digital nomad visa, remote work visa, entrepreneur visa and five-year income for non-residents.

The Startup Law also defines what the government considers a startup by setting an age limit of less than five years from its inception (extended to seven years for companies in sectors such as biotechnology, energy and industry).

This is an area where Mas believes the law has not had a significant impact. He believes that while early-stage startups are supported, late-stage startups that have the potential to make it big suddenly find themselves without support after the five-year period.

“A more flexible and longer tax policy would not only allow startups to grow, but also to become important drivers of sustainable economic development in Spain,” explains Mas. “An expansion of tax incentives based on the size and age of startups would greatly benefit the Spanish innovation ecosystem, promoting scalability, talent retention and international competitiveness.” In addition, Mas said, it would encourage greater investment in innovation, encouraging the creation of skilled jobs and reduces the risk of business failure.

In fact, in his report, Draghi highlighted the lack of late-stage capital and argued that more European funding should also be made available to promote and reward startups that have achieved the success they need to move to the next level to reach.

Mas has also found that established companies don't seek partnerships with startups often enough. Such partnerships could actually be mutually beneficial, with the former providing capital and commercialization expertise and the latter offering innovation and agility.

Patricia Pastor, founder and general partner of NextTier Ventures and chair of VDS, sees the difference in funding models and ecosystems helping European and US tech brands achieve international status. In a recent opinion piece, she notes that while early-stage capital is easier to come by in Europe, US startups need to prove their value to investors early on:

“As a European startup grows, it faces other challenges, such as finding growth-stage funding and attracting investors and talent from individual centers such as London. In the United States, these things may be further apart geographically, but they are in the same country.”

In their view, adopting a revenue-based funding model would help European startups prepare for expansion across the region by initially focusing on dominating local markets and then gradually moving into new markets across the bloc.

Draghi's report also puts forward the idea of ​​an EU-wide legal statute (called the “Innovative European Company”) to support rapid growth in the European market. This status, the report says, would provide companies with a single digital identity, valid across the EU and recognized by all Member States, and access to harmonized legislation on company law and insolvency, as well as some key aspects of labor law and the enable taxation. It would also allow them to set up subsidiaries across the EU without setting up separately in each member state.

Attract talent

As Barcelona grapples with reports of a reaction from residents to the growing number of digital nomads who have moved there because of new visa options, Valencia is welcoming them with open arms.

“The situation in Valencia is not comparable to what is happening in Barcelona. Citizens are very clear about the wealth and diversity that digital nomads bring and the positive impact they have on the economy and society,” says Mas.

However, he is concerned about the ability of late-stage companies to retain and continue to attract the talent they need to grow. He believes extending the deferral period on stock options taxation to 10 years would help late-stage startups not only attract but also retain talent.

Startup Valencia has been working to facilitate the soft landing of digital nomads by offering advice on everything from taxes, immigration and banking to networking opportunities.

“In this sense, VDS plays a fundamental role, being one of the most important international technology events in Southern Europe and a platform that transforms Valencia into a global technology center.”

Join Nacho Mas, Patricia Pastor and other thought leaders from the European tech ecosystem as they gather at VDS2024 on October 23-24 to discuss the policies and initiatives that could help Europe close the innovation gap.

Categories
Sport

The White Sox lose to the Tigers and undergo their MLB document 121st defeat of the season

  • Jesse Rogers, ESPN staff writerSeptember 27, 2024, 9:19 p.m. ET

    Close

      Jesse joined ESPN Chicago in September 2009 and covers MLB for ESPN.com.

DETROIT – They could only avoid it for so long.

After a mini-winning streak that went down in history for a few days, the Chicago White Sox finally suffered their 121st loss of the year, the worst defeat by a team in a season in modern MLB history.

The record was set Friday night in a 4-1 loss to the Detroit Tigers.

“I think the frustration was long before the numbers,” interim manager Grady Sizemore said afterwards. “Again, I think it's one of those things where you're still not happy, but I don't know if I would feel any different if we were at 115 or 110. It’s still a frustrating year.”

In front of a sellout Comerica crowd, the Tigers secured a postseason berth for the first time since 2014. Detroit won for the 39th time since the All-Star break, the same record as the White Sox all season.

Editor's Tips

2 relatives

“Obviously it sucks,” said Garrett Crochet, who started for the White Sox and did not make a decision Friday. “We put ourselves in this position early on. We had a bad April. We just never fought our way out of that hole. We are where we are because of how we played, which sucks.”

Chicago's record losing season included a 21-game losing streak and two separate 14-game losing streaks. They started the year 1–9 and by May 1st they were 14.5 games out of first place with a run differential of minus-84. By June 1st they were 13.5 games out of fourth place in the AL Central.

“It's been an extremely difficult year for everyone,” said outfielder Gavin Sheets. “It was mentally and physically tough. I'm sorry for everyone in this room to be a part of this. Seeing Detroit celebrate was just four years ago. It's frustrating. It doesn’t feel good.”

The White Sox's fall was steep. In 2021, they won 93 games and captured an AL Central Division title – but then the decline began.

They finished 2022 with a .500 record, following a 101-loss season last season. After a difficult start this year, the team traded away starter Erick Fedde, closer Michael Kopech and veteran hitter Tommy Pham in July.

Things only got worse. The White Sox lost their first 17 games after the All-Star break, part of that AL-record 21-game losing streak.

“It doesn’t sit well with either of us,” Sheets said. “But unfortunately that’s where we are right now. It is the job of everyone in this room to ensure that we move forward and that this never happens again.”

The White Sox tied the 1962 Mets for the most losses in a season last weekend when they were swept by the Padres, but they won their last three home games before Friday's historic loss to the Tigers. These victories provided a glimmer of hope that the White Sox might not hold the record, but they had to beat the Tigers to prevent that. It didn't happen.

(Walk) South Sider

The White Sox fall to 39-121 (.244) this season, passing the 1962 Mets for the second-most losses of all time and the most in modern history. The 1899 Cleveland Spiders hold the MLB record with 134 losses:

Year team losses
1899 Cleveland Spiders 134
2024 White Sox 121
1962 Mets 120
2003 tiger 119
1916 Philadelphia Athletics 117

Sheets was asked how he felt when Detroit secured the Finals.

“I didn’t know how I was going to feel about it,” Sheets said. “All the time, the difference between 120 and 121 is neither a better season nor a greater success. … Since we had three wins in a row, we thought maybe we could do something special and stick it out and win six in a row, and you start to believe it and think maybe it won't happen.

“And suddenly, the last time, you realize that you are on the wrong side of history. It hurt a little more than I expected.”

Crochet struck out six in his final game of the year, but relievers Jared Shuster and Fraser Ellard gave up runs in the fifth and seventh innings to secure their 121st loss. Crochet was a bright spot for Chicago, finishing the season with the highest strikeout rate (12.9) per nine innings pitched of any player in baseball. But his use was limited as he was a starter in his first year and the team simply didn't have enough behind him.

The team also struggled at the plate. The White Sox rank last in runs scored and have the third-highest ERA in baseball. They also played poor baseball, leading to the firing of former manager Pedro Grifol last month.

A dismal clubhouse tried to find the positives in a miserable season.

“Everyone in this room knows we’re going to be together for a while,” Sheets said. “We are a young group. It's not like guys are looking ahead to the next phase of their careers. Everyone is trying to come together in this room and support each other.”

“There is not much support outside of this space. So we come together and rely on our staff and coaches and everyone around us and support each other.”

Sizemore echoed Sheets' message. The former Cleveland outfielder is in the running for the permanent job, but that wasn't on his mind after Friday's loss.

“We’re just focused on ourselves and getting better, and we know we can still improve a lot,” he said. “But I think we have the right people and the right personnel to get this under control.”

Categories
Health

FDA approves Bristol Myers Squibb's schizophrenia drug

Cobenfy drug from Bristol Myers Squibb

Courtesy: Bristol Myers Squibb

The Food and Drug Administration gave approval Thursday Bristol Myers SquibbCobenfy, the highly anticipated schizophrenia drug, is the first novel treatment for the debilitating, chronic mental disorder in more than seven decades.

Schizophrenia affects the way a person thinks, feels, and behaves and can cause paranoia, delusions, hallucinations, and changes in emotions, movements, and behavior. These symptoms can interfere with a patient's daily life, making it difficult for them to go to school or work, socialize, and perform other daily activities. Most people are diagnosed in their late teens to early 30s.

Bristol Myers Squibb expects the twice-daily pill, sold under the brand name Cobenfy, to be available in late October, executives told CNBC. The drug is a much-needed new option for the nearly 3 million adults in the U.S. living with schizophrenia, some medical experts say.

Only 1.6 million of these patients are treated for the disease and 75% of them stop taking it According to the drug manufacturer, they stop taking medications for the first 18 months because they have difficulty finding treatments that are effective or easily tolerated for them.

Cobenfy could also represent a huge long-term revenue opportunity for Bristol Myers Squibb, which is under pressure to offset potential lost sales of top-selling treatments whose patents are expiring. The drug comes from the whopping $14 billion acquisition of biotech company Karuna Therapeutics late last year.

In a July research note, Guggenheim analysts said they view Cobenfy as a “longer-term, multibillion-dollar opportunity” for the company. However, they said the drug will likely be slow to come to market, so it may not make a significant contribution to Bristol Myers Squibb's sales in 2024 and 2025.

“I think there may be a truly transformative moment in the way we treat and talk about schizophrenia. And what you have, unfortunately, is an often disadvantaged population that doesn't get the attention it deserves from a research and health perspective,” Andrew Miller, founder and former president of research and development at Karuna Therapeutics and now an advisor to Bristol Myers Squibb, told CNBC.

“I think the most important moment will be in five or 10 years when we look back and say we actually made a difference,” he continued. “We’ve helped people, we’ve improved outcomes, we’ve given nurses and doctors another tool to use.”

Cobenfy will cost $1,850 for a month's supply, or $22,500 a year without insurance and other discounts, Bristol Myers Squibb executives said.

They said the prices are in line with existing brand-name oral schizophrenia treatments and that they expect most patients, particularly those enrolled in Medicare and Medicaid plans, to have minimal out-of-pocket costs for the drug. According to Bristol Myers Squibb, about 80% of patients living with the disease are covered by government insurance.

The company plans to launch a program to help patients afford Cobenfy, executives added.

It is still unclear to what extent this program will improve access for people without insurance.

Cobenfy will have to compete with some existing schizophrenia drugs – so-called antipsychotic treatments – with lower list prices, particularly generic copycats of brand-name treatments. For example, patients without insurance can get the generic version of an antipsychotic called Abilify for just $16 for 30 once-daily tablets with free coupons from GoodRx.

Existing schizophrenia medications work by directly blocking dopamine receptors in the brain, generally improving patients' symptoms.

However, they come with a long list of serious potential side effects that may cause patients to discontinue treatment, including weight gain, excessive fatigue and involuntary, uncontrollable movements. According to WebMD, about a third of people with schizophrenia are also resistant to conventional antipsychotic treatments.

Cobenfy is the first drug approved in a new class of drugs that do not directly block dopamine to improve the symptoms of schizophrenia, Dr. Bristol Myers Squibb Chief Medical Officer Samit Hirawat told CNBC.

He said part of Cobenfy is a drug called Xanomeline, which activates certain so-called muscarinic receptors in the brain to reduce dopamine activity without causing the side effects associated with antipsychotics. The second part of Cobenfy is called trospium and reduces the gastrointestinal side effects associated with xanomeline, such as nausea, vomiting, diarrhea and constipation.

“The majority of these patients have already taken one or two of these products,” Adam Lenkowsky, chief commercialization officer of Bristol Myers Squibb, told CNBC. “The enthusiasm we are hearing from physicians is the possibility of a patient receiving a treatment without noticing the side effects, but also achieving unprecedented effectiveness.”

More CNBC Health coverage

Lenkowsky said the company expects Cobenfy to eventually become the standard treatment for schizophrenia as doctors learn more about the drug and become more comfortable prescribing it to patients.

But the price could limit the drug's use to patients who have already tried other existing treatments and failed, said Nina Vadiei, clinical associate professor of pharmacotherapy and translational sciences at the University of Texas at Austin College of Pharmacy.

“If it were up to me, I wouldn't necessarily say we need to try X number of antipsychotics first. But I know from experience in a hospital that this probably has to happen primarily because of cost,” said Vadiei, a clinical psychiatric pharmacist who treats patients with schizophrenia at San Antonio State Hospital.

Experimental results and upcoming research

The approval was based on data from three clinical trials that compared Cobenfy with a placebo, as well as two longer-term studies that examined how safe and tolerable the drug is for up to one year. According to Bristol Myers Squibb, Cobenfy met the main goal of the three studies and significantly reduced symptoms of schizophrenia compared to a placebo.

In the studies, Cobenfy mostly resulted in mild to moderate side effects that were primarily gastrointestinal and subsided over time, Miller said.

Bristol Myers Squibb said Thursday's approval for schizophrenia may be just the beginning for Cobenfy.

For example, the company has ongoing late-stage clinical trials evaluating Cobenfy's potential in treating Alzheimer's patients with psychosis. Bristol Myers Squibb said it expects to publish data from these studies in 2026.

The company also plans to study Cobenfy's potential to treat bipolar mania and irritability associated with autism.

“When we think of Cobenfy, we think of it as multiple indications in one product … because we are developing the drug not only for schizophrenia, but also for six other indications,” Hirawat said, pointing to other possible uses for the drug.

—CNBC's Angelica Peebles contributed to this report.

Don't miss these insights from CNBC PRO

Categories
Science

Model of the Messianic Salinity Disaster – Are you achieved with it?

Guest “I couldn't think of this kind of slate if I tried” by David Middleton

By the American Association for the Advancement of Science of America…

While the Messinian salinity crisis and subsequent Zanclean megaflood represent one of the most incredible episodes in geological history… So incredible that the uppermost stage of the Miocene is called Messinian and the lowest stage of the Pliocene Zanclean… There were none mass extinction associated with it.

The AAAS of A article points to a very interesting paper:

Agiadi and her colleagues have now tracked the extinction and subsequent recovery with a comprehensive analysis of most fossils from this region, published today in Science Advances.

Fossils tell of a devastating mass extinction as the Mediterranean dried up

So not only was it not a mass extinction, it was an extinction from which there was a recovery. Why use the word “extinction” at all? Let's move on to the thematic research work:

Biodiversity in the coral reef

Cooling directly affected temperature-sensitive organisms such as the tropical reef-building Z corals and their associated faunas (reef fishes and sharks), as well as bryozoans, and led to local extinctions of large populations, particularly in the eastern Mediterranean (Fig. 1) ( 40). Furthermore, the decline in water temperatures in the Mediterranean allowed an expansion of the distribution of boreal species in the basin during the Messinian, while highly thermophilic relict Tethyan species disappeared. Monegatti and Raffi ( 33 ) found that the MSC caused regional mass disappearances of molluscs but only a limited number of actual extinctions, and that the largest Messinian extinctions occurred in the Atlantic Ocean and were triggered by glaciers TG22, TG20, TG14, and TG12 during the MSC. In the Zanclean, the establishment of psychrospheric water masses in the Atlantic increased these effects (41). For example, the great white shark (Carcharodon carcharias) and the blue shark (Prionace glauca) first appeared worldwide at the Miocene/Pliocene boundary (42) and in the Mediterranean after the MSC (43).

The MSC played a critical role in the local extinction of shallow-water Z coral reefs, but was probably not the primary cause ( 40 , 44 ). As tropical reef corals, Z corals are very sensitive to temperature.

Agiadi et al., 2024

When is an extinction not an extinction? If it is a local extinction. The “limited number of actual extinctions” occurred in the Atlantic Ocean and were triggered by glacial episodes rather than the MSC.

The Messinian salinity crisis and the Zanclean megaflood are clearly “a story of upheaval and battles won and lost.” Gothic stories about profound changes, peaceful times and then great trauma.”

During the late Miocene, the Mediterranean literally dried up, depositing a layer of halite and gypsum about a mile thick (Messinian salinity crisis). Then, in the Early Pliocene, rapid flooding of the Mediterranean occurred (Zanclean megaflood), leading to the formation of the modern Mediterranean. The Zanclean Mega Flood was a doozy. If Gavin Schmidt's Silurian civilization had thrived on the Messinian Salt Flats during the late Miocene, the Zanclean megaflood would have wiped it out without a trace. The transition from the MSC to the Zanclean megaflood marks the transition from the Miocene to the Pliocene. It left a serious mark on the stratigraphic record.

Some reconstructions of the Zanclean megaflood suggest that sea levels in the Mediterranean may have risen by 10 meters per day during the peak of water flow from the Atlantic to the Mediterranean basin.

That's what I call climate change!

“The greatest sea in history is dying”… because an unfounded reference to climate change

The MSC caused the deposition of a thick layer of evaporites (salt, gypsum, anhydrite, etc.) throughout the Mediterranean basin:

Schematic cross section of the Leviathan Basin (Bowman, 2011).

However, this is not a story of extinction and certainly not a story of a mass extinction. We can attribute this to a combination of good science journalism and bad science journalism.

References

Bowman, Steven. (2011). “Regional seismic interpretation of hydrocarbon potential offshore Syria”. GeoArabia. 16.

Konstantina Agiadi et al., Late Miocene transformation of biodiversity in the Mediterranean. Science. Adv. 10eadp1134 (2024). DOI:10.1126/sciadv.adp1134

Like this:

How Load…

Categories
Entertainment

At the moment Present's Dylan Dreyer reveals who may change Hoda Kotb

I knew about 10 minutes before the show startedDylan said. “That’s when I think everyone kind of found out.”

But despite the unexpected news, several members of the Today Show were on hand to support Hoda – the mother of daughters. Haley7, and Hope5 – when she brought the update on air.

“I realized that at 60 it was time for me to turn the page and try something new,” Hoda said through tears. “I remember standing outside and looking at this beautiful group of people with these beautiful signs, and I thought, 'This is what the peak of the wave feels like to me.' And I thought it couldn't get any better and decided that this was the right time for me to move on somehow.

She further shared that she plans to focus more on her family.

“Obviously I had my kids late in life, and I thought they deserved a bigger piece of my time than I did,” she continued. “I feel like we only have a limited amount of time. Despite all this, this is the hardest thing in the world.”

Categories
Science

One other constructing block of life can deal with the sulfuric acid from Venus

Venus is often described as a hellscape. The surface temperature exceeds the melting point of lead, and although its atmosphere is dominated by carbon dioxide, it contains enough sulfuric acid to meet the comparison with Hades.

But conditions in Venus' vast atmosphere are not uniform. There are places where some of life's building blocks could withstand the planet's inhospitable nature.

Among the rocky planets, Venus has by far the largest atmosphere in terms of volume. While its surface is inhospitable, its atmosphere features regions that are most Earth-like compared to any other part of the solar system. Scientists have wondered whether life could survive in parts of the planet's upper atmosphere, and the discovery of the potential biomarker phosphine (although this was later disproved) sparked further interest.

Some research suggests that life may exist in Venus' voluminous clouds. Photo credit: Abreu et al. 2024.

One reason Venus keeps coming up in discussions about habitability is that it is accessible, whereas exoplanets are not. Venus is easy to reach and we currently have an orbiter in place, the Japanese Akatsuki spacecraft. Three more missions to Venus are planned for the mid-2030s: NASA's Veritas and DAVINCI and ESA's EnVision.

Nobody is convinced that we will find life on Venus. But the planet can teach us a lot about chemistry and biology and their limitations.

In new research, a team of scientists tested various building blocks in Venus-like conditions to see if they could withstand the planet's dangerous nature. The research is: “Simple lipids form stable higher-order structures in concentrated sulfuric acid.” The lead author is Daniel Duzdevich from the Department of Chemistry at the University of Chicago. The paper is currently in pre-print and has been submitted to the journal Astrobiology.

The surface of Venus is not a candidate for habitability. But there may be regions in its atmosphere. The problem is that much of Venus's sulfuric acid is concentrated in individual clouds rather than distributed throughout the atmosphere.

“The surface of Venus is sterilizing, but the cloud cover includes regions with temperatures and pressures conventionally considered to be compatible with life. However, it is believed that Venus clouds consist of concentrated sulfuric acid,” the authors explain.

Cloud structure in Venus's atmosphere in 2016, revealed by observations in Akatsuki's two ultraviolet bands. Photo credit: Kevin M. Gill

They wanted to test whether some of the “fundamental features” of life could withstand the challenging environment of Venus. Can the chemistry of life resist sulfuric acid?

“Organic chemistry in concentrated sulfuric acid is rarely studied, but is surprisingly extensive. “Recent work supports the idea that complex organic molecules, including amino acids and nucleobases, can be stable in this unusual solvent,” the authors write.

If simple organic molecules can remain stable in sulfuric acid, it is an interesting observation in favor of life. But more complexity is needed, and that is exactly what this research focuses on.

“A fundamental feature of life is cellularity: the distinction between “inside” (the contents of a cell, including information, molecules, and all their interactions) and “outside” (the environment), as well as a mechanism for communication and exchange between the two.” , write Duzdevich and his co-researchers.

The researchers focused on lipids, the membranes that define cells. Lipids are the basis of cell structure, not only as membranes between cells, but also as membranes that form certain parts of the cell's interior. “The cell membrane is particularly important in extreme environments because it must help maintain the homeostasis of the intracellular environment against otherwise harsh external conditions,” the authors write.

The researchers conducted laboratory experiments to determine whether lipids could withstand the harsh environment of Venus. They asked two questions: Can simple lipids resist degradation by sulfuric acid and can the lipids form stable higher-order structures, as they do in cells?

The researchers put large amounts of lipids into vials, exposed them to different concentrations of sulfuric acid, and measured each vial at specific time intervals. Their results show that some lipids can survive exposure to acid and even form structures.

This research illustration shows the vesicle-like structures that formed after concentrated sulfuric acid was added to solid lipids. Each panel is a different area of ​​the same sample taken on the same day. Subsequent images showed that the structures were still intact after seven days. Image source: Duzdevich et al. 2024.

Interested readers can explore the detailed chemistry themselves.

In summary, the results indicate that stable membranes can form and persist in the presence of sulfuric acid. Life uses water as a solvent because it is a polar molecule, can form networks of hydrogen bonds, has a high heat capacity, and is naturally abundant on Earth. But it is not abundant everywhere.

Crucially, this study shows that some aspects of the chemistry of life do not require water as a solvent. Instead, they can tolerate and use sulfuric acid as a solvent. “Here we demonstrate the unexpected stability of complex membrane structures in another polar solvent: concentrated sulfuric acid,” the authors write.

What does this mean for exoplanet habitability and astrobiology?

“Concentrated sulfuric acid as a planetary solvent could be widespread on exoplanets, either on exo-Venuses or on other rocky planets that have dried out due to the stellar activity of their parent star,” the researchers explain.

And of course sulfuric acid is present in large quantities on Venus.

“Concentrated sulfuric acid is also present in our immediate planetary environment as the dominant liquid in the clouds of Venus, further underscoring its importance to planetary science, planetary habitability, and astrobiology,” the authors write.

The question of whether life could somehow survive in the clouds of Venus will not go away. We're new to astrobiology and just can't rule everything out. It may seem far-fetched, but science is a game of evidence, and evidence can be surprising.

This study doesn't provide evidence that can answer the question – big questions like this are answered step by step – but it does provide an interesting result.

“By demonstrating the stability of lipid membranes in this aggressive solvent, we have taken a significant step forward in exploring the potential habitability of the concentrated sulfuric acid cloud environment on Venus,” the authors conclude.

Like this:

How Load…

Categories
Health

Wegovy may subsequent face Medicare drug pricing negotiations

Boxes of Novo Nordisk's Ozempic and Wegovy are seen at a pharmacy in London, Britain, March 8, 2024.

Hollie Adams | Reuters

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health news straight to your inbox. Subscribe here to receive future editions.

Good day! Wegovy, the blockbuster weight loss treatment from Novo Nordiskleads the list of drugs that could soon be part of the second round of price negotiations between manufacturers and Medicare.

That's according to an article published last week in the Journal of Managed Care & Specialty Pharmacy. By February, the government will unveil the next 15 most expensive Medicare Part D drugs that will be the subject of discussions, with price changes taking effect in 2027.

The Biden administration last month announced new negotiated prices for the first 10 Medicare Part D drugs selected for talks. These prices will take effect in 2026.

Drugs that contain the same active ingredient and are manufactured by the same company are considered a single drug, according to Centers for Medicare & Medicaid Services guidelines for discussion. For that reason, researchers expect that all three of Novo Nordisk's branded drugs that contain semaglutide – Wegovy, the diabetes injection Ozempic and an older diabetes pill called Rybelsus – will be selected as a single product for the interviews.

That can be a big deal for older adults seeking these treatments, each of which costs about $1,000 per month (without insurance). But it's still unclear how much Medicare could reduce these costs — and by how much patient costs would fall after insurance and rebates.

The Biden administration, lawmakers and patient advocates have long criticized the Danish drugmaker for the high list prices of its obesity and diabetes drugs. Lars Fruergaard Jørgensen, CEO of Novo Nordisk, faced a debate in the Senate on Tuesday over these prices.

Novo Nordisk CEO Lars Jorgensen testifies before a Senate Health, Education, Labor and Pensions Committee hearing on U.S. prices for the weight loss drugs Ozempic and Wegovy on Capitol Hill in Washington, United States, on September 24, 2024 .

Piroschka Van De Wouw | Reuters

While Jørgensen did not commit to lowering prices for Wegovy and Ozempic, he promised to work with pharmacy benefit managers “on anything that helps patients maintain access and affordability.” When asked about the possible selection of Wegovy and Ozempic, he also dismissed negotiations over Medicare pricing, calling the talks “price-fixing” that will have negative consequences for drug innovation.

Medicare Part D does not cover weight loss treatments unless they are approved and prescribed for another health condition. But Wegovy could be on the list of negotiations because it is now approved to reduce the risk of serious cardiovascular complications, which the researchers say makes it likely that some Part D plans have begun covering the treatment.

CMS guidance requires drugs to be on the market without generic competition for at least seven years before Medicare can select them for price negotiations. Semaglutide will be on the market for seven years and one month by February and there are no generic equivalents.

Other researchers and Wall Street analysts have said they expect Ozempic to be in negotiations because Medicare Part D spends so much on the treatment.

The program spent more than $5.6 billion on semaglutide drugs in 2022, which only reflects spending on Ozempic and Rybelsus because Wegovy was not covered at the time, the paper said. Researchers also predicted that Medicare Part D spent nearly $7.5 billion on Ozempic and Rybelsus in 2023, which is $3 billion more than spending on the second-highest eligible drug.

They noted that they had likely “underestimated” their projected spending figures for semaglutide

Other drugs expected to be in price discussions include: GSK's Trelegy Ellipta, a prescription inhaler used to treat asthma and chronic obstructive pulmonary disease, and Xtandi, a rheumatoid arthritis drug from Astellas Pharma.

Still, researchers said the final list of drugs chosen will depend on whether generic versions hit the market before February.

We'll be closely following the next round of Medicare drug pricing negotiations, so stay tuned for our coverage.

Feel free to send tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

The latest in health tech: Particle Health files antitrust lawsuit against Epic Systems

Data startup Particle Health filed an antitrust lawsuit Monday against Epic Systems, a software provider that stores medical records for about 280 million patients in the United States

Particle alleges that Epic is using its dominance in the electronic health records space to stifle competition in other markets that use this data. The lawsuit was filed in the Southern District of New York.

Oracle and Meditech are other leaders in the electronic health records segment, and patients often have their data stored with multiple providers. Still, Epic is a formidable competitor. The company has the largest acute care market share in the U.S., covering more than half of all multi-specialty acute care beds, according to a report from KLAS Research. Additionally, Epic was the only provider to see a net increase in this market share in 2023, the report said.

Particle's lawsuit comes after the two companies clashed over data sharing practices earlier this year. Epic and Particle are both part of an interoperability network called Carequality, which enables comprehensive exchange of patient information.

Epic filed a formal complaint with Carequality in March, citing concerns that Particle and its participating organizations “may be misrepresenting the purpose associated with their data retrievals.” To join the Carequality network, organizations must be approved to share patient records and adhere to “Permitted Purposes,” which are generally related to treatment.

In its 81-page complaint, Particle said Epic's dispute was “fake” and that Epic alleged that some Particle customers, not Particle itself, improperly obtained records. Particle said Epic used its “outsized influence” over Carequality to achieve a positive outcome and argued that it suffered harm as a result of Epic's conduct.

“If there are no consequences, Epic will have an incentive to apply this playbook again the next time a competitor emerges,” Particle said in a press release Monday.

Epic said it will “vigorously defend itself against Particle's baseless claims” and will continue to protect patient privacy.

“Particle’s claims are baseless. “This lawsuit attempts to divert attention from the real issue: Particle’s unlawful actions on the Carequality health information exchange network violate the HIPAA Privacy Rule,” an Epic spokesperson said in a statement to CNBC on Tuesday. “Particle’s complaint misrepresents Carequality’s decision, which effectively proposes to block Particle customers who have accessed patient data for improper purposes.”

It will likely be a while before there is a final decision, as antitrust cases often move slowly. Google, for example, lost an antitrust case last month that was originally filed in 2020. A US federal judge ruled that the company illegally held a monopoly on text advertising and search.

You can read the full particle complaint against Epic here.

Feel free to send tips, suggestions, story ideas and data to Ashley at ashley.caroot@nbcuni.com.

Categories
Sport

Giants QB Daniel Jones should discover a steadiness between ball safety and splash performs

  • Jordan Raanan, ESPN staff writerSeptember 26, 2024, 6:00 a.m. ET

    Close

      Jordan Raanan is a reporter for NFL Nation at ESPN. Raanan covers the New York Giants. You can follow him on Twitter @JordanRaanan.

EAST RUTHERFORD, NJ – There was one play Daniel Jones made in his first career start that convinced the New York Giants and most of their fans that this was their next great quarterback. It came in the third quarter of a thrilling come-from-behind win in Week 3 against the Tampa Bay Buccaneers in the 2019 season.

Jones, No. 6 at the start of the year, was under pressure from the right side. He easily slipped into the pocket to his left, scanned the field, and fired a bomb outside the platform across his body, 150 feet in the air. According to NFL Next Gen Stats, it was such a hard throw that it only had a 37% chance of success.

But this particular throw was special because the ball flew from the left hash mark deep downfield to the right hash, over safety Mike Edwards and away from cornerback Vernon Hargreaves III. It landed in the hands of rookie receiver Darius Slayton for a stunning 46-yard gain just short of the end zone.

The Giants scored moments later on a touchdown pass from Jones to Sterling Shepard. But it's that throw against Slayton that still resonates a little over five years later, not because of its importance in that game, but because, puzzlingly, it is no longer part of Jones' arsenal. As a rookie, he had 35 close calls in 12 starts. That number has declined every season since.

That earlier version of Jones is gone. The young and promising rookie who threw the ball down the field regularly and without regard for the impact – he threw 24 touchdown passes in his rookie season and hasn't come close since, most of which were 15 in 2022 – hardly exists anymore and doesn't show up at all anymore except on the rarest of occasions, like last year in Week 2 against the Cardinals, when he opened the game and sent out several times against the speedy Jalin Hyatt as the Giants rallied for a 31-28 win.

It appears to be getting late for Jones and the Giants. He is in his sixth season as a starter and must find the right balance between the gunslinger of his rookie year and his more conservative current form. The coming weeks, starting with Thursday's game against NFC East rival Dallas Cowboys (8:15 p.m. ET, Prime Video), will be about figuring out where the quarterback who passed the ball to Slayton in Tampa Bay went sent – ​​and whether he can show up again.

THIS DANIEL JONES is larger and stronger than the 2019 version – but has more calluses. He is nowhere near as aggressive as his younger self.

“It’s still in the DJ space, and I think there are times where you still see flashes of it,” Slayton said. “But we spent two years on it [Giants coaches] I'm just trying to play defense and [the offense] don't make mistakes.

Daniel Jones on the outlook for this season: “I played more, saw more, learned and improved.” Nic Antaya/Getty Images

Jones averaged 7.8 air yards per attempt as a rookie in coach Pat Shurmur's offense. That's down to just 6.7 yards per attempt from 2020 to today. Even in his best season in 2022, Jones averaged 6.0 air yards per attempt, ranking 33rd out of 33 qualified quarterbacks. It's at 6.2 this season.

Turnovers have certainly decreased as a result (from 1.8 per game in his first two professional seasons to 0.9 per game since), but splash plays have also decreased.

“You don’t want to lose that gunslinger mentality,” Jones said. “I think you want to understand when these opportunities arise and when you should take advantage of them. And you’re always trying to balance that.”

Jones' future is uncertain. The Giants made that clear this offseason when they attempted to trade for his replacement in the draft.

“This is Daniel’s year,” general manager Joe Schoen said on “Hard Knocks” this summer. “It was planned the whole time [to] give it a few years. Is he our man for the next 10 years? Or do we have to turn around and find someone else?”

Catch up on NFL Week 3

• Insights and questions from each game
• Graziano: Overreactions (ESPN+)
• Barnwell: Four Wild Surprises (ESPN+)
• Best and Worst Fantasy Game (ESPN+)
• Full Week 3 Scoreboard » | More “

Jones struggled in the opener but bounced back with strong performances against the Washington Commanders and Cleveland Browns. His three-week QBR is 52.7, which ranks him 16th out of 31 qualified quarterbacks. He didn't attempt to throw more than 20 yards through the air in the opening game and is 1 of 8 for 28 yards this season. That one completion came when rookie receiver Malik Nabers hit a Browns cornerback in Week 3 Ball wrestled out of his hands and head.

Now it's time to test where they stand against a Cowboys team that beat them 40-0 in Week 1 at MetLife Stadium last year.

“I played more, saw more, learned and improved,” Jones said. “Of course it didn't go particularly well last time, but we're confident, it's a new team. We’re a new team, they’re a new team, and we’re excited about the opportunity.”

THE GIANTS FIRED Shurmur and replaced him in 2020 with Joe Judge, who brought in former Cowboys coach Jason Garrett as his coordinator. This continued until Garrett was fired midway through the 2021 season and replaced by former Browns coach Freddie Kitchens.

They combined to go 10:23 in the 2020 and 2021 seasons. The offense and Jones struggled. This regime tried so hard to unhinge Jones that Slayton believed it had done irreparable damage.

“Every day someone tells you, ‘Hey, don’t turn it around. Don't turn it over, don't turn it over, don't turn it over,'” Slayton said. “You just go out there and try not to turn the ball over. … It's like when they try to preach a certain way of playing, you adapt to it.

“Every day someone tells you, ‘Hey, don’t turn it around. Don't turn it over, don't turn it over, don't turn it over,'” Darius Slayton says of Jones. “You just go out there and try not to turn the ball over.” Kim Klement-USA TODAY Sports

Jones' aggressiveness seemed to tip toward the other end of the spectrum during Judge's tenure, when he became super conservative. The prudence entering his psyche was not the only contributing factor.

Owner John Mara acknowledged when he hired GM Schoen and coach Brian Daboll in 2022 that the Giants had already done everything they could to “screw this kid up.” The boy is Jones. The constant turnover of coaches and offensive coordinators, combined with a poor offensive line and no true No. 1 receiver, Mara said the Giants have done it all.

Jones was shocked. He has been sacked 187 times since entering the league in 2019, the third-highest number in that span. The more hits he takes, the harder it becomes to stay confident in the pocket. This lack of confidence causes his eyes to droop. It speeds up his reading, or worse, he doesn't manage to finish it at all, even when there is time. He settles for the checkdown too quickly. According to an offensive line coach familiar with Jones, these could all be consequences of the situation.

JONES' FUTURE HINGES directly on his performance this season. He's due $30 million next year, but the Giants can get out of the deal with a manageable $22 million in dead money.

His contract contains an appropriate exit clause after this year, just in case. It will take a wonderful rest of the season before the Giants want to come back.

They need to see Jones play better than he did in 2022, which earned him the four-year, $160 million contract. That year he threw 15 touchdown passes and five interceptions and scored another seven points. The Giants signed Jones with the intention that he could improve and become a top-five quarterback, with the hope that he could develop into a 30-plus touchdown player. That's what the team needs to see, or some version of it, for him to be the long-term answer at quarterback.

“The advantage is that I have great confidence in our employees and Daniel's work ethic [Daboll and Jones’] “The relationship will continue to grow and Daniel will continue to improve,” Schoen said after signing Jones. “If he’s at his bottom right now, I’m really excited to see what his ceiling is going to be.”

The league's perception of Jones appears to be markedly different from improved vision.

Editor's Tips

1 relative

“Maybe a bridge starter,” one NFL general manager said of his value as a free agent if the Giants released him after the season. “It’s probably a situation where he’s competing for the start.”

The $30 million he's due next season would be a “relative bargain” if he's a good starter, the manager said. That makes it possible to sign a quarterback and keep Jones.

“They weren’t afraid to draft [a quarterback to compete with Jones] “This year,” said the manager. “Why should that change?”

That probably wouldn't be the case as long as Jones continued to play well. The Giants insist his confidence isn't an issue. The quarterback said the same thing. The results of the last two weeks on the road against Washington and Cleveland seem to confirm his belief.

Daboll spoke last week about a study he commissioned from his analytics team on throwing the ball 20 yards downfield. They concluded that winning teams did this 3.5 times per game earlier this season. The Giants threw four deep passes against the Commanders and four last week against the Browns after having zero in Week 1.

Maybe they are moving in the right direction. The Giants spent all spring and summer moving the ball downfield. Your quarterback will have this new message drilled into his head.

“You want to get your shots when you get them,” Jones said. “I definitely try to do that when I can.”

“You don’t want to lose that gunslinger mentality,” says Daniel Jones. Nic Antaya/Getty Images

Daboll is considered a quarterback guru. He's running the offense this season and now has three games under his belt as a playcaller with Jones. Daboll dictates the “shot” plays and expects his quarterback to execute them.

“Certainly if he has the right looks, I think he can do it,” Daboll said.

Jones has been doing that for the last two weeks, although without much success. Part of it has to do with the opposition's defense. The Giants had the sixth-most passing snaps against the Cover 2 defense at 18.5%. The Cover 2 defense protects the back end of the field with two deep safeties and asks the quarterback to opt for underneath or intermediate routes.

Jones looks down, only to see the safety in the depths. In week 1 he panicked when it wasn't there, hesitated and showed too much indecision. Daboll noticed after Week 2 that Jones was more decisive in his reads. After what he's been through over the last five years, it remains a work in progress.

All of this could make it even harder to envision Jones regaining the aggressiveness of his 2019 rookie self. Or even an improved version in New York.

“If you went to driving school and all they showed you were videos of fatal car accidents,” an NFL assistant said, “you would probably be a careful driver, too.”

Categories
Technology

Report: Enterprise capital investments in European protection expertise will attain a document $1 billion in 2024

After increasing fivefold since 2018, VC investment in European defense technology is expected to reach a record year in 2024 and is on track to reach $1 billion.

Europe is currently at the centre of an investment boom as governments turn to the defence technology sector to bolster national security in response to escalating geopolitical instability, according to a new report from Dealroom.

“As we face war on European soil for the first time in decades, the urgency to strengthen our security and build a modern defense software stack has never been greater,” said Jeannette zu Fürstenberg, managing director and European head of VC firm General Catalyst.

Zu Fürstenberg added that start-ups play a “crucial role” in this. “Their agility, speed and in-depth technical know-how are indispensable.”

Back to business with the TNW conference

It's time to set your goals and budget for the year ahead! Get 2 tickets now and save €€€ with this Super EarlyBird fare. Limited offer.

Over the past three years, defense technology startups and scaleups have raised $3 billion in venture capital, according to the report. The sector now accounts for 1.8% of total European VC funding – and has more than tripled since 2022.

Germany at the top

Germany, the UK and France dominate the investment, attracting 87% of the total financing. Specifically, the three countries have raised a combined $2.2 billion since 2018.

Over the last six years, investments in Germany alone exceeded those in the UK, the Nordic countries, the Netherlands and Switzerland combined.

Of all European cities, Munich has attracted the most investors, thanks in part to Helsing's $487 million capital raising in 2024. Bristol and Paris are the next major investment centers.

In addition to Bristol, five other British locations made it into the top ten, including London (4th), Reading (5th), Oxford (6th), Leeds (8th) and Cambridge (9th).

The NATO countries invest large sums

According to the report, venture capital investments in European defense technology start-ups are outpacing investment growth across the NATO group by 25 percent.

However, there is an increasing flow of capital in all member countries, with the USA taking the leading position.

Overall, venture capital investments by NATO countries have quadrupled since 2018. The Alliance is now on track to close 2024 with $5.9 billion, bringing total investments in defense technology made by NATO startups since 2018 to $18 billion.

There are now 370 VC-backed startups in NATO countries with a total enterprise value of 161 billion US dollars.